A poison pill is a defensive plan a company’s board adopts to make a hostile takeover prohibitively expensive. Formally called a shareholder rights plan, it gives every existing shareholder the right to buy additional stock at a steep discount the moment an outside buyer crosses a set ownership threshold, usually somewhere between 10% and 20% of outstanding shares. The discount floods the market with cheap new shares, diluting the hostile bidder’s stake so badly that seizing control becomes financially absurd. The point is rarely to actually blow up a deal. The point is to force the bidder to negotiate with the board instead of buying the company out from under it.
How the Trigger and Dilution Work
When a board adopts a rights plan, it issues one right per share to every existing stockholder. Those rights sit dormant, attached to the common stock, doing nothing until someone crosses the ownership trigger. The board sets the trigger, typically at 10% to 20% of outstanding shares, though specialized plans can go as low as 4.9%.
Once the trigger is crossed, the rights activate. Every shareholder except the hostile bidder can exercise their rights to buy new shares at a substantial discount, typically 50% below market price. If a company’s stock trades at $80, rights holders could buy shares worth $160 for an exercise price of $80. Two-for-one, in effect. The hostile bidder is locked out and watches their ownership percentage collapse as millions of new discounted shares hit the register.
The math is brutal. A bidder holding 20% before the trigger can find that stake cut to single digits almost overnight. Regaining the same percentage would require spending far more than the acquisition was ever worth. That threat alone usually does the job. Pills are almost never actually triggered, because rational bidders don’t walk into the trap. The deterrent works precisely because everyone can see what would happen if it fired.
The Three Main Types of Poison Pill
Not every pill is built the same way. Three designs dominate, each protecting shareholders at a different stage.
Flip-In Pills
The flip-in is the standard design and the one most companies adopt. When the ownership trigger is crossed, existing shareholders other than the bidder can buy the target company’s own shares at a deep discount. The dilution hits the bidder immediately, before any merger or acquisition closes. This has been the default structure since the late 1980s.
Flip-Over Pills
A flip-over pill activates later, after the hostile bidder has already gained control and attempts a follow-up transaction like a merger or asset sale. At that point, the target’s shareholders gain the right to buy the acquiring company’s shares at a steep discount. The acquirer’s own shareholders then suffer the dilution, making the second-step transaction punishingly expensive. Even if a bidder gets through the front door, the flip-over ensures the next step carries a heavy price.
Back-End Pills
A back-end pill, sometimes called a note purchase rights plan, takes a different route. Instead of issuing discounted shares, it gives shareholders the right to exchange their stock for cash or preferred securities at a price set by the board, usually above market value. This forces the acquirer to negotiate with the board rather than buying shares from individual shareholders on the open market. The catch: if the acquirer offers more than the back-end price, the defense collapses, because shareholders will simply take the higher bid.
How Boards Adopt and Maintain a Pill
Adopting a pill is fast. The board passes a resolution, appoints a rights agent (usually the company’s existing transfer agent) to handle the administrative mechanics, and distributes the rights as a dividend attached to existing common shares. Shareholders don’t vote. The whole process can happen in a single board meeting, which is the point. Hostile bids can materialize quickly, and the board needs to respond in kind.
Duration has changed significantly over the past decade. The current norm, driven by institutional investors and proxy advisory firms, is a one-year term. ISS will generally recommend that shareholders vote against board nominees at companies that maintain a long-term pill without shareholder approval, and Glass Lewis takes a similar line. That pressure has made the short-term, shareholder-ratified pill the practical standard for any company that cares about institutional investor support.
Some plans include a Three-year Independent Director Evaluation (TIDE) provision, which requires a committee of independent directors to review the pill at least every three years and recommend whether to modify or terminate it. That adds a governance layer without forcing immediate expiration.
Some boards have tried to insulate their pills from proxy contests through “dead hand” provisions, which allow only the directors who originally adopted the pill (or their approved successors) to redeem it. A newly elected board friendly to a bidder would inherit a pill it couldn’t remove. A related “slow hand” variant delays new directors’ ability to redeem for a set period after taking office. ISS recommends voting against directors at any company with these features, and Delaware courts have signaled that dead hand and slow hand provisions face severe scrutiny because they undermine the shareholder franchise.
How a Hostile Bidder Gets Around a Pill
A pill is an obstacle, not a wall. Bidders have several paths through it.
Board Redemption
The simplest path is to convince the board to redeem the rights voluntarily. Boards can cancel the rights for a nominal price, usually a few cents each. This typically happens once the bidder raises its offer to a price the board considers fair, or once whatever threat prompted the pill has passed. Redemption turns a hostile deal into a negotiated one, which is how these situations usually end. The pill doesn’t block the deal. It forces a better price.
Qualifying Offer Clauses
Some pills include a “qualifying offer” provision that creates a contractual bypass. If the bidder’s offer meets specific criteria, usually a fully financed all-cash or all-shares offer held open for a minimum period, the pill either doesn’t trigger or shareholders can vote to override the board’s refusal to redeem. Nearly 60% of institutional investors surveyed by ISS consider this feature important enough that it should be in every pill. The clause is a safety valve against boards that might use the pill to entrench themselves rather than to negotiate.
The Proxy Contest
When the board won’t redeem and no qualifying offer clause exists, the bidder’s remaining option is to replace the board. A proxy contest asks shareholders to elect new directors who will redeem the pill and approve the deal. This runs alongside the hostile tender offer as a dual-track campaign: vote for our directors and tender your shares.
Here the pill’s interaction with a classified (staggered) board becomes decisive. If the target elects directors in staggered classes, one-third each year, the bidder can’t replace a majority in a single election. It takes two annual meeting cycles, meaning the fight stretches over at least a year. A poison pill paired with a staggered board is the most formidable defense in corporate law. Delaware courts have held the combination isn’t inherently impermissible, provided the bidder still has a realistic opportunity to wage a proxy contest.1Justia Law. Blasius Industries Inc v Atlas Corp
When Courts Will Strike a Pill Down
A board’s legal right to adopt a pill doesn’t mean every pill survives judicial review. Delaware courts apply the enhanced scrutiny test from Unocal Corp. v. Mesa Petroleum (1985). The test has two parts. First, the board must show reasonable grounds for believing a genuine threat to the company existed. Second, the defensive response must be proportional to that threat, not so extreme that it locks shareholders out of any meaningful choice.2Legal Information Institute. Enhanced Scrutiny Test
The threat prong requires more than vague anxiety. A board can’t adopt a pill just because it heard rumors, or because it wants to insulate itself from shareholder activism. In 2021, the Delaware Court of Chancery struck down a poison pill adopted by The Williams Companies during the COVID-19 pandemic, calling it “the most extreme version of a poison pill” the court had ever seen. The board had set a 5% trigger and openly stated the pill was designed to block “all forms of stockholder activism,” but couldn’t identify any actual threat. Both prongs of the Unocal test failed.
The proportionality prong has teeth of its own. A pill can’t be preclusive, meaning it can’t make it impossible for shareholders to receive any offer, and it can’t be coercive. Courts give boards significant deference, but that deference has limits, and extreme or exotic pill features tend to find those limits quickly.
A related standard comes from Revlon, Inc. v. MacAndrews & Forbes Holdings (1986). Once a board decides to sell the company, its job shifts from long-term stewardship to getting the best price reasonably available. Keeping a pill in place at that point to block a higher bid becomes very hard to justify. And under the Blasius standard, any board action taken for the primary purpose of interfering with a shareholder vote requires a “compelling justification,” a heavier burden than Unocal alone.
The statutory foundation for all of this comes from Section 157 of the Delaware General Corporation Law, which authorizes corporations to create and issue rights or options to acquire shares on terms set by the board.3Delaware Code Online. Delaware Code Title 8 Chapter 1 Subchapter V The 1985 Moran v. Household International decision confirmed that the statute is broad enough to cover shareholder rights plans, and hundreds of public companies adopted pills in the years that followed.4Justia Law. Moran v Household Intern Inc
NOL Poison Pills Are a Separate Case
Not every pill is about blocking a takeover. Companies with significant net operating loss (NOL) carryforwards sometimes adopt pills specifically to protect those tax assets. Under Section 382 of the Internal Revenue Code, a company’s ability to use its NOLs can be sharply limited if an “ownership change” occurs, defined roughly as a more-than-50-percentage-point shift in ownership among major shareholders over a three-year rolling period.5Harvard Law School Forum on Corporate Governance. The Misplaced Focus of the ISS Policy on NOL Poison Pills
To prevent that shift, NOL pills set their ownership trigger much lower, usually at 4.9%, just below the 5% threshold that matters under Section 382. The structure mirrors a traditional pill, but the purpose is preserving future tax deductions rather than repelling a hostile bidder. NOL pills also tend to run longer than takeover pills, typically three years, with expiration tied to the exhaustion of the NOLs rather than an arbitrary sunset.5Harvard Law School Forum on Corporate Governance. The Misplaced Focus of the ISS Policy on NOL Poison Pills
Do Poison Pills Help or Hurt Shareholders?
This is genuinely contested, and honest people disagree.
The argument for pills is straightforward. They prevent a bidder from acquiring the company on the cheap by forcing a negotiation. Shareholders of target companies tend to receive higher premiums in negotiated deals than in uncontested tender offers, and the pill is the reason the negotiation happens at all. Without it, a bidder could accumulate shares in the open market, bypass the board entirely, and pressure scattered shareholders into accepting a lowball price.
The argument against pills is equally intuitive. They give boards the power to block deals shareholders might actually want. A board saying “this offer undervalues the company” might be right, or might be protecting its own jobs. Empirical research has found that the most restrictive forms of pill defenses are associated with higher rates of defeated tender offers and modest negative effects on stock prices when adopted. The concern is that some boards use the pill not as a bargaining tool but as a bunker.
The practical resolution has been governance constraints rather than abolition. Short durations, shareholder ratification requirements, qualifying offer clauses, independent director review, and proxy advisory firm oversight collectively limit the entrenchment risk without eliminating the negotiating leverage that makes pills useful in the first place. A well-designed pill with a one-year term and a qualifying offer provision looks very different from a permanent pill with a dead hand feature, and courts, investors, and proxy advisors treat them accordingly.